Promising Study Shows Novel Antibody Blocking Cancer Cells and Stabilizing Disease
Read Transcript
Download Transcript 
Share This Video
Take Our SurveyExciting research about a PD1 antibody was discussed at the big ASCO 2012 meeting of oncologists and researchers. The hope is a new drug could allow a patient’s own immune system to renew its attack against cancer cells. As investigator Dr. Scott Tykodi from the Seattle Cancer Care Alliance explains, the antibody appears to be effective against three cancer types: kidney cancer, melanoma, and non small cell lung cancer. While new trials will begin, there are patients who participated in the earlier clinical trials alive today one and two years after they were told with standard therapy they had only months to live.
Get Email Updates:
Get updated automatically when new content about Clinical Trials has been posted.
Privacy Policy
Privacy Policy
Clinical TrialsMore Health Topics
Experts & Guests
|
Scott S. Tykodi, M.D., Ph.D.
Assistant Professor, Division of Medical Oncology, Seattle Cancer Care Alliance
Dr. Scott Tykodi is assistant professor in the Division of Medical Oncology at the Seattle Cancer Care Alliance. As a medical oncologist and lead investigator, Dr. Tykodi’s focus is in the application of immune therapies to treat various cancers. His clinical expertise includes cancer immunotherapy, renal cell carcinoma, hematopoietic cell transplantation and clinical trials. He received his medical degree from...
more >
|
|
|
